Ghent University Academic Bibliography

Your filters: cql: author="Barnett, Michael" or (type any "bookEditor issueEditor" and editor="Barnett, Michael")

Add to list
- Journal Article
- A1
- open access
Real-world effectiveness of ocrelizumab in relapsing multiple sclerosis : an MSBase registry sub-study

Helmut Butzkueven, Pamela Farr, Serkan Ozakbas, Cavit Boz, Tomas Kalincik, Lisa Taylor, Anneke Van Der Walt, Raed Alroughani, Katherine Buzzard, Olga Skibina, et al.

(2026) MULTIPLE SCLEROSIS AND RELATED DISORDERS. 106.
Add to list
- Journal Article
- A1
- open access
Haematopoietic stem cell transplant versus immune-reconstitution therapy in relapsing multiple sclerosis

Tomas Kalincik, Sifat Sharmin, Izanne Roos, Mark S Freedman, Harold Atkins, Jennifer Massey, Ian Sutton, Barbara Withers, Joachim Burman, Øivind Torkildsen, et al.

(2026) BRAIN.
Add to list
- Journal Article
- A2
- open access
Relationship between brain atrophy and disability in a multi-site multiple sclerosis registry

Ai-Lan Nguyen, Dana Horakova, Eva H Havrdova, Michael Barnett, Maria Pia Sormani, Nicola De Stefano, Marco Battaglini, Manuela Vaneckova, Elaine Lui, Frank Gaillard, et al.

(2025) BMJ NEUROLOGY OPEN. 7(2).
Add to list
- Journal Article
- A1
- open access
First-year treatment response predicts the following 5-year disease course in patients with relapsing-remitting multiple sclerosis

Simona Toscano, Tim Spelman, Serkan Ozakbas, Raed Alroughani, Clara G. Chisari, Salvatore Lo Fermo, Alexandre Prat, Marc Girard, Pierre Duquette, Guillermo Izquierdo, et al.

(2025) NEUROTHERAPEUTICS. 22(2).
Add to list
Standardized definition of Progression Independent of Relapse Activity (PIRA) in relapsing-remitting multiple sclerosis

Jannis Müller, Sifat Sharmin, Johannes Lorscheider, Serkan Ozakbas, Rana Karabudak, Dana Horakova, Bianca Weinstock-Guttman, Vahid Shaygannejad, Masoud Etemadifar, Raed Alroughani, et al.

(2025) JAMA NEUROLOGY. 82(6). p.614-625
Add to list
- Journal Article
- A1
- open access
Four years on : pregnancy and birth outcomes reported in the MSBase pregnancy, neonatal outcomes, and Women’s Health Registry (2020–2024)

Vilija G Jokubaitis, Raed Alroughani, Ayse Altintas, Sara Eichau, Stella Hughes, Barbara Willekens, Dana Horakova, Eva Kubala Havrdova, Serkan Ozakbas, Cavit Boz, et al.

(2025) MULTIPLE SCLEROSIS JOURNAL. 31(9). p.1088-1101
Add to list
- Journal Article
- A1
- open access
Pregnancy-related disease outcomes in women with moderate to severe multiple sclerosis disability

Jessica Shipley, Heidi N. Beadnall, Paul G. Sanfilippo, Wei Zhen Yeh, Dana Horakova, Eva Kubala Havrdova, Pavel Hradilek, Tomas Kalincik, Izanne Roos, Alexandre Prat, et al.

(2025) JAMA NETWORK OPEN. 8(9).
Add to list
- Journal Article
- A1
- open access
Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis

Izanne Roos, Sifat Sharmin, Charles Malpas, Serkan Ozakbas, Jeannette Lechner-Scott, Suzanne Hodgkinson, Raed Alroughani, Sara Eichau Madueño, Cavit Boz, Anneke van der Walt, et al.

(2024) MULTIPLE SCLEROSIS JOURNAL. 30(9). p.1163-1175
Add to list
- Journal Article
- A1
- open access
Disease-modifying therapies in managing disability worsening in paediatric-onset multiple sclerosis : a longitudinal analysis of global and national registries

Sifat Sharmin, Izanne Roos, Charles B Malpas, Pietro Iaffaldano, Marta Simone, Massimo Filippi, Eva Kubala Havrdova, Serkan Ozakbas, Vincenzo Brescia Morra, Raed Alroughani, et al.

(2024) LANCET CHILD & ADOLESCENT HEALTH. 8(5). p.348-357
Add to list
- Journal Article
- A1
- open access
Comparison between dimethyl fumarate, fingolimod, and ocrelizumab after natalizumab cessation

Chao Zhu, Tomas Kalincik, Dana Horakova, Zhen Zhou, Katherine Buzzard, Olga Skibina, Raed Alroughani, Guillermo Izquierdo, Sara Eichau, Jens Kuhle, et al.

(2023) JAMA NEUROLOGY. 80(7). p.739-748

Academic Bibliography

Real-world effectiveness of ocrelizumab in relapsing multiple sclerosis : an MSBase registry sub-study

Haematopoietic stem cell transplant versus immune-reconstitution therapy in relapsing multiple sclerosis

Relationship between brain atrophy and disability in a multi-site multiple sclerosis registry

First-year treatment response predicts the following 5-year disease course in patients with relapsing-remitting multiple sclerosis

Standardized definition of Progression Independent of Relapse Activity (PIRA) in relapsing-remitting multiple sclerosis

Four years on : pregnancy and birth outcomes reported in the MSBase pregnancy, neonatal outcomes, and Women’s Health Registry (2020–2024)

Pregnancy-related disease outcomes in women with moderate to severe multiple sclerosis disability

Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis

Disease-modifying therapies in managing disability worsening in paediatric-onset multiple sclerosis : a longitudinal analysis of global and national registries

Comparison between dimethyl fumarate, fingolimod, and ocrelizumab after natalizumab cessation

Contents

Support

Contact